RA CAPITAL MANAGEMENT, L.P. - 29 Aug 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
SPRY
Transactions as of
29 Aug 2023
Net transactions value
+$23,250,000
Form type
4
Filing time
31 Aug 2023, 17:26:46 UTC
Previous filing
22 Aug 2023
Next filing
25 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Purchase $23,250,000 +3,750,000 +178% $6.20 5,856,774 29 Aug 2023 See Footnotes F1, F2, F4
holding SPRY Common Stock 902,904 29 Aug 2023 See Footnotes F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 29, 2023, the Fund (as defined in footnote (2)) entered into a contract to purchase the shares from a third-party seller in a privately negotiated transaction.
F2 These shares are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 These shares are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F4 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Dr. Peter Kolchinsky, a Managing Partner of the Adviser, serves on the Issuer's board of directors.